Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Liposomal ellagic acid enhances the regenerative potential of ADMSC-laden nanofibrous PCL scaffolds in a rat model of spinal cord injury.

Abroumand Gholami A., Rahmani S., Moharreri P., Amirazodi E., Molavi AM., Mokhtari T.

Animal Study with a reported sample of 10 on Spinal Cord Injury, Chronic Inflammation, published in Sci Rep (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Sci Rep (2025)
Country
England
Reported sample size
10
Source database
PubMed
PMID
40825827
PMCID
PMC12361420
DOI
10.1038/s41598-025-15789-w
Citations
5

Abstract (original English)

Spinal cord injury (SCI) leads to myelin breakdown and extensive neuronal loss around the injury site due to increased oxidative stress. This study aims to develop a comprehensive platform incorporating scaffolds, therapeutic agents, and stem cells to restore structures and pathways in SCI. Scaffolds were created through the electrospinning of a PCL/functionalized multi-walled carbon nanotube (f-MWCNTs) composite, which was then coated with liposomal ellagic acid (EA@lip) and seeded with adipose-derived mesenchymal stem cells (ADMSCs). The optimal drug concentration was determined by conducting MTT and DPPH assays through three different time points. After assessing the biocompatibility and anti-inflammatory properties of the scaffolds for ADMSCs, the implant was tested in a rat model of dorsal hemisection. The female Wistar rats were divided into six groups (n = 10): Sham, SCI, SCI + PCL/f-MWCNTs (PCs), SCI + scaffolds + EA@lip (PC/N), SCI + scaffolds + ADMSCs (PC/C), and SCI + scaffolds + EA@lip + ADMSCs (PC/N/C). In the second week, biochemical analyses were conducted to evaluate oxidative stress in the animals' blood. Throughout the study, the motor function of the animals was monitored. After six weeks, the rats were subjected to real-time PCR and histological analysis, utilizing Cresyl Violet/Luxol Fast Blue staining and evaluating the expression of the genes COX2, GPX1,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsSpinal Cord InjuriesEllagic AcidLiposomesMesenchymal Stem CellsRatsFemaleNanofibersTissue ScaffoldsRats, Wistar

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research